{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:13:55Z","timestamp":1793812435936,"version":"4.6.1"},"reference-count":128,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Netherlands Heart Foundation","award":["2020B005 and 01-003-2022-0358"],"award-info":[{"award-number":["2020B005 and 01-003-2022-0358"]}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["CoG 818715"],"award-info":[{"award-number":["CoG 818715"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019802","name":"BioTechMed-Graz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Netherlands Heart Foundation and FWF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Partnership Fostering a European Research Area for Health","award":["101095426"],"award-info":[{"award-number":["101095426"]}]},{"name":"EU Horizon Europe Research and Innovation Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is no consensus on an age cut-off for being considered elderly, but the majority of patients with heart failure (HF) have an advanced age. The lifetime risk for developing HF is \u223c25%, with a sharp increase in incidence after the age of 70. The lifetime risk for men and women is almost equal, but women exhibit a higher propensity towards developing HF with preserved ejection fraction, whereas men are more prone to HF with reduced ejection fraction. During the biological ageing process, several systemic and local pathophysiological alterations impact the myocardium, including impaired autophagy and proteostasis, mitochondrial dysfunction, and oxidative stress, as well as cellular senescence, clonal haematopoiesis of indeterminate potential, and chronic low-grade inflammation or inflammaging. Collectively, these changes compromise cardiac energy homeostasis and promote cell loss and dysfunction, increasing the risk of HF. Despite their relevance, these ageing-related mechanisms are hitherto not addressed by guideline-recommended medical therapy. Guideline-recommended medical therapy remains the cornerstone of HF treatment across age groups, including in elderly patients who tolerate it. However, a high burden of comorbidities and several features specific to advanced age, such as low blood pressure and frailty, often preclude full-dose guideline-recommended medical therapy. Similarly, the risk\u2013benefit ratio of device therapies needs careful consideration in light of competing non-cardiac risks due to comorbidities that are prevalent in this population. Finally, HF is a mortal condition, and advanced care planning and end-of-life decisions should be discussed in a timely manner in elderly patients.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag110","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:25:54Z","timestamp":1770035154000},"page":"3052-3064","source":"Crossref","is-referenced-by-count":19,"title":["Heart failure in the elderly: epidemiology, mechanisms, and management"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9140","authenticated-orcid":false,"given":"Rudolf A","family":"de Boer","sequence":"first","affiliation":[{"name":"Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC , Dr. Molewaterplein 40, Rotterdam 3015GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5042-9054","authenticated-orcid":false,"given":"Mahmoud","family":"Abdellatif","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-117X","authenticated-orcid":false,"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-7865","authenticated-orcid":false,"given":"Veronique L","family":"Roger","sequence":"additional","affiliation":[{"name":"National Institutes of Health National Heart Blood and Lung Institute, , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"2026062219570248100_ehag110-B1","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/eurheartj\/ehae868","article-title":"Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years","volume":"46","author":"van Essen","year":"2025","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B2","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1093\/eurheartj\/ehaf231","article-title":"Healthy ageing in older adults with cardiovascular disease","volume":"46","author":"Schmanske","year":"2025","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yjmcc.2022.03.008","article-title":"Heart failure with preserved ejection fraction: an age-related condition","volume":"167","author":"Abdellatif","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026062219570248100_ehag110-B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.yjmcc.2022.04.006","article-title":"Aging and HFpEF: are we running out of time?","volume":"168","author":"Withaar","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026062219570248100_ehag110-B5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cvr\/cvae177","article-title":"Anti-ageing interventions for the treatment of cardiovascular disease","volume":"121","author":"Abdellatif","year":"2025","journal-title":"Cardiovasc Res"},{"key":"2026062219570248100_ehag110-B6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jchf.2024.02.021","article-title":"Aging in heart failure: embracing biology over chronology: JACC family series","volume":"12","author":"Goyal","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026062219570248100_ehag110-B7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/acel.12601","article-title":"Molecular and physiological manifestations and measurement of aging in humans","volume":"16","author":"Khan","year":"2017","journal-title":"Aging Cell"},{"key":"2026062219570248100_ehag110-B8","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ Res"},{"key":"2026062219570248100_ehag110-B9","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"key":"2026062219570248100_ehag110-B10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ejhf.1768","article-title":"The Heart Failure Association Atlas: rationale, objectives, and methods","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The heart failure association atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B12","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/ejhf.3710","article-title":"Insights into the European heart failure epidemiology","volume":"27","author":"Seferovi\u0107","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B13","doi-asserted-by":"publisher","first-page":"S1071-9164(25)00326-4","DOI":"10.1016\/j.cardfail.2025.07.007","article-title":"HF STATS 2025: heart failure epidemiology and outcomes statistics an updated 2025 report from the Heart Failure Society of America","author":"WRITING COMMITTEE MEMBERS","year":"2025","journal-title":"J Card Fail"},{"key":"2026062219570248100_ehag110-B14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamacardio.2024.0615","article-title":"Reversals in the decline of heart failure mortality in the US, 1999 to 2021","volume":"9","author":"Sayed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026062219570248100_ehag110-B15","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.116.025941","article-title":"Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012","volume":"135","author":"Christiansen","year":"2017","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jchf.2017.12.006","article-title":"Innovation in heart failure treatment: life expectancy, disability, and health disparities","volume":"6","author":"Van Nuys","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026062219570248100_ehag110-B17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.116.025795","article-title":"Ejection fraction: misunderstood and overrated (Changing the Paradigm in Categorizing Heart Failure)","volume":"135","author":"Konstam","year":"2017","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B18","doi-asserted-by":"publisher","first-page":"e181456","DOI":"10.1001\/jamanetworkopen.2018.1456","article-title":"Variability in ejection fraction measured by echocardiography, gated single-photon emission computed tomography, and cardiac magnetic resonance in patients with coronary artery disease and left ventricular dysfunction","volume":"1","author":"Pellikka","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2026062219570248100_ehag110-B19","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/heartjnl-2020-317604","article-title":"What is \u2018normal\u2019 left ventricular ejection fraction?","volume":"106","author":"Hudson","year":"2020","journal-title":"Heart"},{"key":"2026062219570248100_ehag110-B20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12933-024-02566-8","article-title":"Caloric restriction and its mimetics in heart failure with preserved ejection fraction: mechanisms and therapeutic potential","volume":"24","author":"Fuerlinger","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026062219570248100_ehag110-B21","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1093\/eurheartj\/ehu216","article-title":"Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)","volume":"35","author":"Wong","year":"2014","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ejhf.1029","article-title":"Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Gorter","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B23","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1093\/eurheartj\/ehaf216","article-title":"Obesity accelerates cardiovascular ageing","volume":"46","author":"Ruperez","year":"2025","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B24","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/j.amjmed.2019.10.030","article-title":"Risk factors for heart failure in the community: differences by age and ejection fraction","volume":"133","author":"Chamberlain","year":"2020","journal-title":"Am J Med"},{"key":"2026062219570248100_ehag110-B25","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011\u20132020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"key":"2026062219570248100_ehag110-B26","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jacc.2019.06.053","article-title":"Cardiovascular aging and heart failure","volume":"74","author":"Triposkiadis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1161\/CIRCRESAHA.118.312208","article-title":"Autophagy in cardiovascular aging","volume":"123","author":"Abdellatif","year":"2018","journal-title":"Circ Res"},{"key":"2026062219570248100_ehag110-B28","doi-asserted-by":"publisher","first-page":"656201","DOI":"10.3389\/fcell.2021.656201","article-title":"Targeting the mitochondria-proteostasis axis to delay aging","volume":"9","author":"Zimmermann","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026062219570248100_ehag110-B29","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.109.904557","article-title":"Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies","volume":"121","author":"Predmore","year":"2010","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B30","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1038\/s41467-021-23272-z","article-title":"Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover","volume":"12","author":"Martin","year":"2021","journal-title":"Nat Commun"},{"key":"2026062219570248100_ehag110-B31","doi-asserted-by":"publisher","first-page":"e029938","DOI":"10.1161\/JAHA.123.029938","article-title":"Dysregulated autophagy and sarcomere dysfunction in patients with heart failure with co-occurrence of P63A and P380S BAG3 variants","volume":"12","author":"Martin","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026062219570248100_ehag110-B32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/CIRCULATIONAHA.120.050498","article-title":"Myocardial gene expression signatures in human heart failure with preserved ejection fraction","volume":"143","author":"Hahn","year":"2021","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jacc.2021.11.059","article-title":"Impact of autophagy on prognosis of patients with dilated cardiomyopathy","volume":"79","author":"Kanamori","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B34","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/nm.4222","article-title":"Cardioprotection and lifespan extension by the natural polyamine spermidine","volume":"22","author":"Eisenberg","year":"2016","journal-title":"Nat Med"},{"key":"2026062219570248100_ehag110-B35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.115.020502","article-title":"Drp1-Dependent mitochondrial autophagy plays a protective role against pressure overload-induced mitochondrial dysfunction and heart failure","volume":"133","author":"Shirakabe","year":"2016","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B36","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.jacc.2018.02.066","article-title":"Trehalose-induced activation of autophagy improves cardiac remodeling after myocardial infarction","volume":"71","author":"Sciarretta","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B37","doi-asserted-by":"publisher","first-page":"e13751","DOI":"10.1111\/acel.13751","article-title":"High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: evidence for a phylogenetically conserved proaging function of ACBP","volume":"22","author":"Mont\u00e9gut","year":"2023","journal-title":"Aging Cell"},{"key":"2026062219570248100_ehag110-B38","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1093\/eurheartj\/ehad661","article-title":"Actionable autophagy checkpoints in cardiovascular ageing","volume":"44","author":"Abdellatif","year":"2023","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026062219570248100_ehag110-B40","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026062219570248100_ehag110-B41","doi-asserted-by":"publisher","first-page":"108710","DOI":"10.1016\/j.pharmthera.2024.108710","article-title":"Targeting organ-specific mitochondrial dysfunction to improve biological aging","volume":"262","author":"Madreiter-Sokolowski","year":"2024","journal-title":"Pharmacol Ther"},{"key":"2026062219570248100_ehag110-B42","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.119.040551","article-title":"Unlocking the secrets of mitochondria in the cardiovascular system: path to a cure in heart failure\u2014a report from the 2018 national heart, lung, and blood institute workshop","volume":"140","author":"Tian","year":"2019","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B43","first-page":"I80","article-title":"Mitochondrial structure and function in acute myocardial ischemic injury","volume":"38","author":"Jennings","year":"1976","journal-title":"Circ Res"},{"key":"2026062219570248100_ehag110-B44","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.tem.2023.11.004","article-title":"Mitochondrial quality control pathways sense mitochondrial protein import","volume":"35","author":"Lee-Glover","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"2026062219570248100_ehag110-B45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41577-022-00760-x","article-title":"Mitochondrial control of inflammation","volume":"23","author":"Marchi","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2026062219570248100_ehag110-B46","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/CIRCRESAHA.112.268946","article-title":"Mitochondrial control of cellular life, stress, and death","volume":"111","author":"Galluzzi","year":"2012","journal-title":"Circ Res"},{"key":"2026062219570248100_ehag110-B47","doi-asserted-by":"publisher","first-page":"e14138","DOI":"10.1111\/eci.14138","article-title":"Metabolic control of mitophagy","volume":"54","author":"Zimmermann","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"2026062219570248100_ehag110-B48","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCRESAHA.124.323800","article-title":"Mitochondrial structure and function in human heart failure","volume":"135","author":"Hinton","year":"2024","journal-title":"Circ Res"},{"key":"2026062219570248100_ehag110-B49","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","article-title":"Myocardial substrate metabolism in the normal and failing heart","volume":"85","author":"Stanley","year":"2005","journal-title":"Physiol Rev"},{"key":"2026062219570248100_ehag110-B50","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.118.036259","article-title":"Mitochondrial dysfunction in heart failure with preserved ejection fraction","volume":"139","author":"Kumar","year":"2019","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B51","doi-asserted-by":"publisher","first-page":"e003190","DOI":"10.1161\/JAHA.115.003190","article-title":"Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure","volume":"5","author":"Hunter","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026062219570248100_ehag110-B52","doi-asserted-by":"publisher","first-page":"e004129","DOI":"10.1161\/CIRCHEARTFAILURE.117.004129","article-title":"Fatigability, exercise intolerance, and abnormal skeletal muscle energetics in heart failure","volume":"10","author":"Weiss","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026062219570248100_ehag110-B53","doi-asserted-by":"publisher","first-page":"e55513","DOI":"10.7554\/eLife.55513","article-title":"Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice","volume":"9","author":"Chiao","year":"2020","journal-title":"Elife"},{"key":"2026062219570248100_ehag110-B54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11897-022-00539-0","article-title":"Mitochondria as therapeutic targets in heart failure","volume":"19","author":"Schwemmlein","year":"2022","journal-title":"Curr Heart Fail Rep"},{"key":"2026062219570248100_ehag110-B55","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/eurheartj\/ehad028","article-title":"Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration","volume":"44","author":"Nollet","year":"2023","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B56","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cardfail.2020.02.001","article-title":"Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial","volume":"26","author":"Butler","year":"2020","journal-title":"J Card Fail"},{"key":"2026062219570248100_ehag110-B57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.freeradbiomed.2018.01.012","article-title":"MitoQ improves mitochondrial dysfunction in heart failure induced by pressure overload","volume":"117","author":"Ribeiro Junior","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"2026062219570248100_ehag110-B58","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jchf.2014.06.008","article-title":"The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial","volume":"2","author":"Mortensen","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026062219570248100_ehag110-B59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40268-021-00372-1","article-title":"Coenzyme Q10 in the treatment of heart failure with preserved ejection fraction: a prospective, randomized, double-blind, placebo-controlled trial","volume":"22","author":"Samuel","year":"2022","journal-title":"Drugs R D"},{"key":"2026062219570248100_ehag110-B60","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/14651858.CD008684.pub3","article-title":"Coenzyme Q10 for heart failure","volume":"2","author":"Al Saadi","year":"2021;","journal-title":"Cochrane Database Syst Rev"},{"key":"2026062219570248100_ehag110-B61","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.121.056589","article-title":"NAD+ metabolism in cardiac health, aging, and disease","volume":"144","author":"Abdellatif","year":"2021","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B62","doi-asserted-by":"publisher","first-page":"eabd7064","DOI":"10.1126\/scitranslmed.abd7064","article-title":"Nicotinamide for the treatment of heart failure with preserved ejection fraction","volume":"13","author":"Abdellatif","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026062219570248100_ehag110-B63","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1161\/CIRCULATIONAHA.116.026099","article-title":"Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy","volume":"137","author":"Diguet","year":"2018","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B64","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/eurheartj\/ehaf062","article-title":"Autophagy is required for the therapeutic effects of the NAD+ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction","volume":"46","author":"Abdellatif","year":"2025","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B65","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1080\/15548627.2025.2522127","article-title":"NAD+ repletion restores cardioprotective autophagy and mitophagy in obesity-associated heart failure by suppressing excessive trophic signaling","volume":"21","author":"Abdellatif","year":"2025","journal-title":"Autophagy"},{"key":"2026062219570248100_ehag110-B66","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jacbts.2022.06.012","article-title":"Safety and tolerability of nicotinamide riboside in heart failure with reduced ejection fraction","volume":"7","author":"Wang","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"2026062219570248100_ehag110-B67","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/eurheartj\/ehz961","article-title":"Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease","volume":"41","author":"Liberale","year":"2020","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B68","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41569-023-00881-3","article-title":"Hallmarks of cardiovascular ageing","volume":"20","author":"Abdellatif","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026062219570248100_ehag110-B69","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026062219570248100_ehag110-B70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00395-024-01032-6","article-title":"Mineralocorticoid receptor promotes cardiac macrophage inflammaging","volume":"119","author":"Fraccarollo","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"2026062219570248100_ehag110-B71","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2009.12.045","article-title":"Inflammatory markers and incident heart failure risk in older adults: the health ABC (Health, Aging, and Body Composition) study","volume":"55","author":"Kalogeropoulos","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B72","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","article-title":"Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction","volume":"72","author":"Tromp","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B73","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC state-of-the-art review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B74","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00011-023-01845-6","article-title":"Inflammation in heart failure: pathophysiology and therapeutic strategies","volume":"73","author":"Boulet","year":"2024","journal-title":"Inflamm Res"},{"key":"2026062219570248100_ehag110-B75","doi-asserted-by":"publisher","first-page":"e033675","DOI":"10.1161\/JAHA.123.033675","article-title":"Prognostic significance and biologic associations of senescence-associated secretory phenotype biomarkers in heart failure","volume":"13","author":"Salman","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026062219570248100_ehag110-B76","doi-asserted-by":"publisher","first-page":"e005133","DOI":"10.1161\/CIRCHEARTFAILURE.118.005133","article-title":"IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and neprilysin inhibition in patients with heart failure","volume":"11","author":"Januzzi","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026062219570248100_ehag110-B77","doi-asserted-by":"publisher","first-page":"e003806","DOI":"10.1161\/CIRCHEARTFAILURE.116.003806","article-title":"Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model","volume":"10","author":"Gevaert","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026062219570248100_ehag110-B78","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/FJC.0000000000000878","article-title":"Senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice","volume":"76","author":"Jia","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026062219570248100_ehag110-B79","doi-asserted-by":"publisher","first-page":"eadi0077","DOI":"10.1126\/scitranslmed.adi0077","article-title":"Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human","volume":"16","author":"Roh","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026062219570248100_ehag110-B80","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cvr\/cvaf030","article-title":"Anti-senescence therapies: a new concept to address cardiovascular disease","volume":"121","author":"Stojanovi\u0107","year":"2025","journal-title":"Cardiovasc Res"},{"key":"2026062219570248100_ehag110-B81","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026062219570248100_ehag110-B82","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jacc.2021.04.085","article-title":"Supplemental association of clonal hematopoiesis with incident heart failure","volume":"78","author":"Yu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B83","doi-asserted-by":"publisher","first-page":"e2353244","DOI":"10.1001\/jamanetworkopen.2023.53244","article-title":"Clonal hematopoiesis and incident heart failure with preserved ejection fraction","volume":"7","author":"Schuermans","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026062219570248100_ehag110-B84","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2021.02.028","article-title":"Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction","volume":"77","author":"Pascual-Figal","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026062219570248100_ehag110-B86","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1161\/CIRCULATIONAHA.123.064170","article-title":"Clonal hematopoiesis in clinical and experimental heart failure with preserved ejection fraction","volume":"148","author":"Cochran","year":"2023","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B87","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2715","article-title":"Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers","volume":"25","author":"Shi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B88","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u03b2\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B89","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"2026062219570248100_ehag110-B90","doi-asserted-by":"publisher","first-page":"i1855","DOI":"10.1136\/bmj.i1855","article-title":"Effect of age and sex on efficacy and tolerability of \u03b2 blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis","volume":"353","author":"Kotecha","year":"2016","journal-title":"BMJ"},{"key":"2026062219570248100_ehag110-B91","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B92","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"2026062219570248100_ehag110-B93","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026062219570248100_ehag110-B94","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jchf.2023.06.020","article-title":"Age, sex, and outcomes in heart failure with reduced EF","volume":"11","author":"Lam","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026062219570248100_ehag110-B95","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/CIRCHEARTFAILURE.110.959890","article-title":"Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial","volume":"4","author":"Haass","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026062219570248100_ehag110-B96","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B97","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B98","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026062219570248100_ehag110-B99","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026062219570248100_ehag110-B100","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jppr.1796","article-title":"Management of heart failure in older people","volume":"52","author":"Warner","year":"2022","journal-title":"Pharm Pract Res"},{"key":"2026062219570248100_ehag110-B101","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/ejhf.3618","article-title":"Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC","volume":"27","author":"Skouri","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B102","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"2026062219570248100_ehag110-B103","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.jacc.2023.02.024","article-title":"Learning to embrace the decline in eGFR after initiation of therapies for heart failure","volume":"81","author":"Coca","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026062219570248100_ehag110-B104","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/ejhf.3150","article-title":"Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)","volume":"26","author":"Mullens","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B105","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/eurheartj\/ehaf480","article-title":"Heart failure with reduced ejection fraction and ventricular secondary mitral regurgitation: a holistic approach","volume":"47","author":"Adamo","year":"2026","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B106","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1093\/eurheartj\/ehac204","article-title":"Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies","volume":"43","author":"Crespo-Leiro","year":"2022","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B107","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/eurheartj\/ehad658","article-title":"Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry","volume":"45","author":"Schmitto","year":"2024","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B108","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1001\/jama.2023.23204","article-title":"Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial","volume":"330","author":"Mehra","year":"2023","journal-title":"JAMA"},{"key":"2026062219570248100_ehag110-B109","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/heartjnl-2022-320909","article-title":"Cardiac resynchronisation therapy with or without a defibrillator: individualising device prescription","volume":"108","author":"Straw","year":"2022","journal-title":"Heart"},{"key":"2026062219570248100_ehag110-B110","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/eurheartj\/ehae334","article-title":"Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study","volume":"45","author":"Veltmann","year":"2024","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B111","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/ehf2.14831","article-title":"The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review","volume":"12","author":"Murray","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026062219570248100_ehag110-B112","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"van Riet","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B113","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026062219570248100_ehag110-B114","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ejhf.3186","article-title":"Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: results of the Amylo-VIP-HF study","volume":"26","author":"Tubben","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B115","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez","year":"2025","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B116","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1093\/eurheartj\/ehad185","article-title":"Digitalis in heart failure: declining use and ongoing outcome trials","volume":"44","author":"van Veldhuisen","year":"2023","journal-title":"Eur Heart J"},{"key":"2026062219570248100_ehag110-B117","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s00392-023-02199-z","article-title":"Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial","volume":"112","author":"Bavendiek","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026062219570248100_ehag110-B118","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ejhf.3575","article-title":"The DIGIT-HF trial: key amendments of study design","volume":"27","author":"Bavendiek","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B119","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ejhf.3428","article-title":"Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial","volume":"26","author":"van Veldhuisen","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B120","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/ejhf.3679","article-title":"DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials","volume":"27","author":"Bavendiek","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B121","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2415471","article-title":"Digitoxin in patients with heart failure and reduced ejection fraction","volume":"393","author":"Bavendiek","year":"2025","journal-title":"N Engl J Med"},{"key":"2026062219570248100_ehag110-B122","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/eurjhf\/hft071","article-title":"Preferences of heart failure patients in daily clinical practice: quality of life or longevity?","volume":"15","author":"Kraai","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B123","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/ejhf.1865","article-title":"Depression and heart failure: the lonely comorbidity","volume":"22","author":"Sbolli","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B124","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/ejhf.2981","article-title":"Palliative care in heart failure guidelines: a comparison of the 2021 ESC and the 2022 AHA\/ACC\/HFSA guidelines on heart failure","volume":"25","author":"Blum","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B125","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/ejhf.1823","article-title":"What is what? From a palliative care approach to specialized palliative care in heart failure management","volume":"22","author":"Jaarsma","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B126","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/eurjhf\/hfp041","article-title":"Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology","volume":"11","author":"Jaarsma","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B127","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/ejhf.1994","article-title":"Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper","volume":"22","author":"Hill","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026062219570248100_ehag110-B128","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00399-019-0623-1","article-title":"[Device therapy in cardiological palliative care situations]","volume":"30","author":"Dutzmann","year":"2019","journal-title":"Herzschrittmacherther Elektrophysiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/24\/3052\/67158672\/ehag110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/24\/3052\/67158672\/ehag110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:57:10Z","timestamp":1782172630000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/24\/3052\/8501419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":128,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2026,2,28]]},"published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag110","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,21]]},"published":{"date-parts":[[2026,2,28]]}}}